A5054745950- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Autoimmune Bullous Skin Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Pharmaceutical studies and practices
- Contact Dermatitis and Allergies
- Urticaria and Related Conditions
- Skin Protection and Aging
- Biosimilars and Bioanalytical Methods
- Spondyloarthritis Studies and Treatments
- Nail Diseases and Treatments
- Food Allergy and Anaphylaxis Research
- Cutaneous Melanoma Detection and Management
- Complementary and Alternative Medicine Studies
- Antifungal resistance and susceptibility
- Medicine and Dermatology Studies History
- Occupational exposure and asthma
- melanin and skin pigmentation
- Autoimmune and Inflammatory Disorders
- Rheumatoid Arthritis Research and Therapies
- Immunodeficiency and Autoimmune Disorders
- Cutaneous lymphoproliferative disorders research
- Pregnancy and Medication Impact
Hospital Universitari Germans Trias i Pujol
2016-2025
Universitat Autònoma de Barcelona
2016-2025
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2022-2024
Hospital Arnau de Vilanova
2021-2024
Oxfam
2020
John Wiley & Sons (United States)
2020
John Wiley & Sons (United Kingdom)
2020
Hudson Institute
2020
Hospital General Universitario de Alicante Doctor Balmis
2020
Hospital Clínico Universitario Virgen de la Victoria
2020
La terapia biológica representa una alternativa bien establecida en el manejo de la psoriasis moderada y grave. Sin embargo, su elevado coste, experiencia relativamente limitada empleo clínico abundancia publicaciones existentes hacen necesario desarrollo unas directrices basadas evidencia científica disponible consenso un grupo expertos. El objetivo ideal del tratamiento es conseguir mantener a largo plazo blanqueamiento completo o prácticamente o, defecto, mínima afectación localizada...
Obesity, particularly abdominal obesity, is currently considered a chronic low-grade inflammatory condition that plays an active role in the development of pathophysiologic phenomena responsible for metabolic syndrome and cardiovascular disease through secretion proinflammatory adipokines cytokines. In recent years clear genetic, pathogenic, epidemiologic links have been established between psoriasis with important implications health. The relationship 2 conditions probably bidirectional,...
Abstract Background Few reported studies compare drug survival in moderate‐to‐severe psoriasis vulgaris. Objectives To describe and of systemic drugs, including biologic agents (infliximab, etanercept, adalimumab ustekinumab) classical drugs (acitretin, ciclosporin methotrexate) psoriasis. Methods This was a multicenter, prospective, cohort study patients receiving therapies between 2008 2013 12 hospitals Spain. Baseline data discontinuation were collected. Drug is presented using...
Background: The efficacy and safety of secukinumab in patients with plaque psoriasis (PsO) have been demonstrated randomized clinical trials (RCTs). However, data regarding its real-life settings are scarce. Objectives: To evaluate the practice PsO attending 10 dermatology centers Spain. Methods: Data from 136 consecutively treated for at least 52 weeks were collected a retrospective observational study. Results: After treatment, 69% 46% achieved PASI-75, PASI-90, respectively. PASI-score ≤5...
Abstract Background There are few data on the prevalence of obesity in general psoriasis population and real impact management patients clinical setting. Objectives To evaluate overweight with moderate‐to‐severe compared to assess relationship between Body Mass Index ( BMI ) risk discontinuing treatment. Methods Patients registered Biobadaderm, a prospective registry, were grouped according different categories Spanish population. Drug survival was analysed considering only drug withdrawal...
Biologic therapy is a well-established strategy for managing moderate and severe psoriasis. Nevertheless, the high cost of such therapy, relatively short span clinical experience with biologics, abundance literature now available on these agents have made evidence-based consensus-based guidelines necessary. The ideal goal psoriasis treatment to achieve complete or nearly clearing lesions maintain it over time. Failing that ideal, would be reduce involvement localized can controlled topical...
Ixekizumab (anti-IL17A) is effective as treatment for moderate-to-severe plaque psoriasis, but real-life data on effectiveness and safety are currently very limited.To evaluate the efficacy of ixekizumab in a cohort psoriasis patients.Retrospective chart review 100 patients with treated at seven Spanish dermatological centres.According to observed analysis, percentage achieving 75% 90% reduction from baseline score Psoriasis Area Severity Index (PASI) was 87.5%-50.0% week 12-16; 88.3%-58.4%...